



Psoriasis Enrollment Form

Phone: 855-425-4085

Fax: 855-425-4096

ardonhealth.com

PATIENT INFORMATION	Patient Name: _____	PRESCRIBER INFORMATION	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Last Four of SS #: _____ Primary Language: _____		Phone: _____ Fax: _____
Height: _____ Weight: _____	Contact Person: _____ Phone: _____		

INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)

Need By Date: _____ **Ship to:** Patient Physician Other: _____

Date of Diagnosis: _____ **Diagnosis:** L40.0 -Psoriasis Vulgaris L40.59 Psoriatic Arthritis Other _____

Prior (FAILED) Therapies	Medication	Reason for Discontinuation	Prior Medication	Medication	Reason for Discontinuation
<input type="checkbox"/> Biologics	_____	_____	<input type="checkbox"/> UVB	_____	_____
<input type="checkbox"/> Methotrexate	_____	_____	<input type="checkbox"/> Topical	_____	_____
<input type="checkbox"/> Oral Meds	_____	_____	<input type="checkbox"/> Other	_____	_____
<input type="checkbox"/> PUVA	_____	_____			

Current Medications: _____ **Is the patient also taking methotrexate?** Yes No

Allergies: _____ **Does the patient have a latex allergy?** Yes No

Is the patient new to therapy? Yes No

BSA affected by Psoriasis _____%

Has patient had positive TB test? Yes No If yes, date of last chest x-ray: _____

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILL
<input type="checkbox"/> Cimzia®	Starter Dose <input type="checkbox"/> Starter Kit (200 mg Prefilled Syringes)	<input type="checkbox"/> 400mg Sub-Q at weeks 0, 2, and 4	<input type="checkbox"/> 1 Kit = 6 x 200 mg/mL PFS	0
	Maintenance Dose <input type="checkbox"/> 200mg/ml Prefilled Syringe <input type="checkbox"/> 200mg Vial	<input type="checkbox"/> 400mg Sub-Q every 4 weeks <input type="checkbox"/> 200mg Sub-Q every 2 weeks <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Carton = 2 x 200 mg/mL PFS <input type="checkbox"/> 1 Carton = 2 x 200 mg Vials	_____
<input type="checkbox"/> Enbrel®	<input type="checkbox"/> 50mg/ml Sureclick™ <input type="checkbox"/> 50mg/ml Prefilled Syringe <input type="checkbox"/> 25mg/0.5ml Prefilled Syringe <input type="checkbox"/> 25mg Vial	<input type="checkbox"/> Psoriasis Induction Dose: Inject 50mg SQ TWICE a week (3-4 days apart) for 3 months, then maintenance dosing.	_____	_____
		<input type="checkbox"/> Psoriasis Maintenance Dose: Inject 50mg SQ ONCE a week.		
		<input type="checkbox"/> Psoriatic Arthritis Dose: Inject 50mg SQ ONCE a week.		
		<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Humira®	<input type="checkbox"/> 40mg/0.8ml Pen <input type="checkbox"/> 40mg/0.8ml Prefilled Syringe	<input type="checkbox"/> Psoriasis Starter dose: Inject 80mg SQ day 1, 40mg Day 8, then 40mg every 14 days thereafter	<input type="checkbox"/> 2 <input type="checkbox"/> 4	_____
		<input type="checkbox"/> Inject 40mg SQ every OTHER week <input type="checkbox"/> Inject 40mg SQ every week <input type="checkbox"/> Other: _____		
<input type="checkbox"/> Simponi®	<input type="checkbox"/> 50mg/0.5ml SmartJect™ <input type="checkbox"/> 50mg/0.5ml Syringe	<input type="checkbox"/> Inject 1 dose (50mg) Sub-Q once monthly	<input type="checkbox"/> 1 (one)	_____
		<input type="checkbox"/> Other: _____		
<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45mg/0.5mL Prefilled Syringe <input type="checkbox"/> 90mg/1mL Prefilled Syringe	<input type="checkbox"/> Initiation Dose: Inject 1 prefilled syringe Sub-Q Day 1	<input type="checkbox"/> 1 PFS	0
		<input type="checkbox"/> Maintenance Dose: Inject the contents of 1 prefilled syringe Sub-Q starting Day 29 & every 12 weeks thereafter	<input type="checkbox"/> 1 PFS	_____
<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> 150mg/mL Prefilled Syringe <input type="checkbox"/> 150mg/mL Pen	<input type="checkbox"/> Psoriasis Initiation Dose: Inject 300mg Sub-Q Day 1, Day 8, Day 15, Day 22, and then every 4 weeks starting on Day 29	<input type="checkbox"/> 8 Pens/PFS	0
		<input type="checkbox"/> Psoriasis Maintenance Dose: Inject the contents of 300mg Sub-Q starting Day 29 & then every 4 weeks thereafter	<input type="checkbox"/> 2 Pens/PFS	_____
		<input type="checkbox"/> Psoriatic Arthritis/Ankylosing Spondylitis Initiation Dose: Inject 150mg Sub-Q Day 1, Day 8, Day 15, Day 22, and then every 4 weeks starting on Day 29	<input type="checkbox"/> 4 Pens/PFS	_____
		<input type="checkbox"/> Psoriatic Arthritis/Ankylosing Spondylitis Maintenance Dose: Inject the contents of 150mg Sub-Q starting Day 29 & then every 4 weeks thereafter	<input type="checkbox"/> 2 Pens/PFS	_____
<input type="checkbox"/> Otezla	<input type="checkbox"/> Otezla Starter Pack <input type="checkbox"/> Otezla 30mg Tablet	<input type="checkbox"/> Initiation Dose: Take as directed per package instructions	<input type="checkbox"/> 1 Starter Kit (55 tablets)	0
		<input type="checkbox"/> Maintenance Dose: Take 1 tablet by mouth twice daily	<input type="checkbox"/> 60 Tablets	_____
<input type="checkbox"/> Remicade®	<input type="checkbox"/> Remicade 100mg vial	<input type="checkbox"/> Induction: Infuse _____mg IV at weeks 0, 2, and 6	<input type="checkbox"/> _____ # Vial(s)	_____
		<input type="checkbox"/> Maintenance: Infuse _____mg IV at every 8 weeks		
X	X			
PRODUCT SUBSTITUTION PERMITTED _____ (Date)	DISPENSE AS WRITTEN _____ (Date)			

Date Needed: _____ Medication Start Date: _____

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 15350301 (12/16)